<DOC>
	<DOCNO>NCT02037230</DOCNO>
	<brief_summary>The investigator ' long-term goal improve survival patient pancreatic cancer enhance efficacy gemcitabine-radiation add Wee1 inhibitor MK-1775 .</brief_summary>
	<brief_title>Dose Escalation Trial AZD1775 Gemcitabine ( +Radiation ) Unresectable Adenocarcinoma Pancreas</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>Patients must pathologically confirm adenocarcinoma pancreas . Patients unresectable disease , define radiographically &gt; 180 degree involvement superior mesenteric artery celiac trunk SMV/portal vein impingement surgically reconstruct , absence distant metastasis.. Patients must Zubrod performance status ( measure general well range 0 5 0 represent perfect health ) &lt; 2 . Patients must adequate organ function define follow : absolute neutrophil count ≥ 1500/mm3 , platelet ≥ 100,000/mm3 , serum creatinine ≤ 2 mg/dl , total bilirubin ≤ 3 , ( relief biliary obstruction present ( PTC tube endobiliary stent ) ) AST &lt; 5 time upper limit normal . Patients reproductive potential must agree use effective contraceptive method participation trial 6 month trial . Patients must breastfeed . Patients must aware investigational nature therapy provide write informed consent . Patients must least 18 year old . Other serious uncontrolled concomitant systemic disorder psychiatric condition would interfere safe delivery protocol therapy . A history previous chemotherapy pancreatic cancer abdominal radiation therapy . The use investigational agent month enrollment study . Inability discontinue prescription nonprescription drug product know metabolized CYP3A4 , inhibit induce CYP3A4 prior Day 1 dose withhold throughout study 2 week last dose study medication . Medications particular concern follow inhibitor CYP3A4 : azole antifungal ( ketoconazole itraconazole , fluconazole voriconazole ) , macrolide antibiotic ( erythromycin , clarithromycin ) , cimetidine , aprepitant , HIV protease inhibitor , nefazodone follow inducer CYP3A4 : phenytoin , barbiturates rifampicin . Substrates CYP3A4 include statin ( lovastatin , simvastatin ) , midazolam , terfenadine , astemizole , cisapride .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>